{{Drugbox
| IUPAC_name = 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]propanamide
| image = Befetupitant_structure.png
| width = 220

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US =
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 290296-68-3
| CAS_supplemental =
| ATC_prefix = none
| ATC_suffix =
| PubChem = 6450815
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 
| ChemSpiderID      = 4953365

<!--Chemical data-->
| C=29 | H=29 | F=6 | N=3 | O=2 
| molecular_weight = 565.550 g/mol
| smiles = CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCOCC4
| StdInChI          = 1S/C29H29F6N3O2/c1-18-7-5-6-8-22(18)23-16-25(38-9-11-40-12-10-38)36-17-24(23)37(4)26(39)27(2,3)19-13-20(28(30,31)32)15-21(14-19)29(33,34)35/h5-8,13-17H,9-12H2,1-4H3
| StdInChIKey       = ZGNPLCMMVKCTHM-UHFFFAOYSA-N
}}

'''Befetupitant''' ('''Ro67-5930''') is a drug developed by [[Hoffmann-La Roche]] which acts as a potent and selective [[Antagonist (pharmacology)|antagonist]] for the [[Tachykinin receptor 1|NK<sub>1</sub>]] [[Receptor (biochemistry)|receptor]].<ref>Hoffmann T, BÃ¶s M, Stadler H, Schnider P, Hunkeler W, Godel T, Galley G, Ballard TM, Higgins GA, Poli SM, Sleight AJ. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. ''Bioorg Med Chem Lett''. 2006 Mar 1;16(5):1362-5. {{PMID|16332435}}</ref> It was originally developed as a potential [[antiemetic]] drug, though development was ultimately discontinued after a related drug [[netupitant]] was deemed to be more suitable for clinical development. Befetupitant has however continued to be researched for other possible applications such as treatment of [[corneal neovascularization]].<ref>Bignami F, Giacomini C, Lorusso A, Aramini A, Rama P, Ferrari G. NK1 receptor antagonists as a new treatment for corneal neovascularization. ''Invest Ophthalmol Vis Sci''. 2014 Sep 16;55(10):6783-94. doi: 10.1167/iovs.14-14553. {{PMID|25228541}}</ref>

== References ==
{{Reflist}}


{{Neurokinin receptor modulators}}

[[Category:NK1 receptor antagonists]]
[[Category:Trifluoromethyl compounds]]

{{nervous-system-drug-stub}}